158 related articles for article (PubMed ID: 30138727)
1. Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.
McClure RF; Ewalt MD; Crow J; Temple-Smolkin RL; Pullambhatla M; Sargent R; Kim AS
J Mol Diagn; 2018 Nov; 20(6):717-737. PubMed ID: 30138727
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
3. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
5. Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results.
Kahraman CY; Sincan G; Tatar A
Eurasian J Med; 2022 Jun; 54(2):181-185. PubMed ID: 35703527
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract][Full Text] [Related]
8. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
Vobugari N; Heuston C; Lai C
Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
[TBL] [Abstract][Full Text] [Related]
9. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
10. Myeloid malignancies: mutations, models and management.
Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
[TBL] [Abstract][Full Text] [Related]
11. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas C; Ayala R; Larráyoz MJ; Chillón MC; Carrillo-Cruz E; Bilbao-Sieyro C; Prados de la Torre E; Martínez-Cuadrón D; Rodríguez-Veiga R; Boluda B; Gil C; Bernal T; Bergua JM; Algarra L; Tormo M; Martínez-Sánchez P; Soria E; Serrano J; Alonso-Domínguez JM; García-Boyero R; Amigo ML; Herrera-Puente P; Sayas MJ; Lavilla-Rubira E; Martínez-López J; Calasanz MJ; García-Sanz R; Pérez-Simón JA; Gómez-Casares MT; Sánchez-García J; Barragán E; Montesinos P; On Behalf Of Pethema Group
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672386
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
13. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
14. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
15. Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms.
Chen D; Weinberg OK
Int J Lab Hematol; 2023 Dec; 45(6):839-844. PubMed ID: 37867386
[TBL] [Abstract][Full Text] [Related]
16. The genetic basis of myelodysplasia and its clinical relevance.
Cazzola M; Della Porta MG; Malcovati L
Blood; 2013 Dec; 122(25):4021-34. PubMed ID: 24136165
[TBL] [Abstract][Full Text] [Related]
17. Designing Myeloid Gene Panels.
Zhao F; Bosler DS; Cook JR
Arch Pathol Lab Med; 2022 Aug; 146(8):1004-1011. PubMed ID: 34784413
[TBL] [Abstract][Full Text] [Related]
18. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
19. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of clonal evolution in myelodysplastic syndromes.
Makishima H; Yoshizato T; Yoshida K; Sekeres MA; Radivoyevitch T; Suzuki H; Przychodzen B; Nagata Y; Meggendorfer M; Sanada M; Okuno Y; Hirsch C; Kuzmanovic T; Sato Y; Sato-Otsubo A; LaFramboise T; Hosono N; Shiraishi Y; Chiba K; Haferlach C; Kern W; Tanaka H; Shiozawa Y; Gómez-Seguí I; Husseinzadeh HD; Thota S; Guinta KM; Dienes B; Nakamaki T; Miyawaki S; Saunthararajah Y; Chiba S; Miyano S; Shih LY; Haferlach T; Ogawa S; Maciejewski JP
Nat Genet; 2017 Feb; 49(2):204-212. PubMed ID: 27992414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
